Fujirebio Diagnostics, Inc. Release: New Ovarian Cancer Test Now Available in Europe

MALVERN, Pa.--(BUSINESS WIRE)--European women facing “the silent killer” now have access to a breakthrough test to identify their risk of ovarian cancer. Fujirebio Diagnostics, the industry leader in biomarker assays, announces that its HE4 test is now CE marked, a mandatory conformity mark on many products placed on the single market in the European Economic Area (EEA). Now available for sale throughout the European Union, the simple blood test measures for a substance known as HE4, which many studies have shown can be elevated in epithelial ovarian cancers. The test is intended to be used in conjunction with the CanAg CA 125 EIA or the Abbott ARCHITECT CA 125 II as an aid in estimating risk of epithelial ovarian cancer in women presenting with a pelvic mass prior to surgery.